Dishman Pharmaceuticals & Chemicals Acquires Creapharm Parenterals
Switzerland-based Carbogen Amcis AG, a leading pharmaceutical process development and API manufacturing company, recently announced the acquisition of Creapharm Parenterals, a subsidiary of France-based Creapharm Group. Creapharm Parenterals (formerly MP5), is a contract development and manufacturing organization (CDMO) specializing in liquid, semi-solid, and injectable aseptic dosage forms. As part of this acquisition, Creapharm Parenterals has changed its name to Carbogen Amcis SAS.
“This exciting transaction further strengthens Carbogen Amcis’ service offerings, enabling us to provide our customers with a complete and reliable manufacturing solution from process development to the supply of pharmaceutical substances and formulated products,” said Mark Griffiths, CEO of Carbogen Amcis.
The acquisition will extend Carbogen Amcis’ comprehensive range of development and manufacturing services by adding complementary formulation, lyophilization services, and sterile GMP capabilities for the fast supply of drug products, including highly potents, for preclinical studies and clinical trials (Phase I, II, and III).
“This move reflects our determination to continue to position Carbogen Amcis as a leading service provider for early phase development projects and niche-scale commercial products within the Dishman Group of Companies,” added Jay Vyas, Managing Director of the Dishman Group and owner of Carbogen Amcis.
Creapharm Parenterals brings over 10 years of expertise in the supply of Investigational Medicinal Products (IMP), with more than 300 batches and 145 clinical batches produced since 2000. The company employs 16 highly qualified specialists and operates a GMP manufacturing site in
Through this acquisition, Carbogen Amcis has added the following services for injectable, liquid, and semi-solid pharmaceutical forms: formulation of new products; optimization of existing formulation; development and optimization of lyophilization cycles; parenterals production of preclinical and clinical batches (Phase I, II, and III); aseptic process validation (Media Fill Testing); GMP capabilities for the development of injectables in liquid or freeze-dried forms; and aseptic filling in vials, syringes, cartridges, and infusion bags
“We believe the combined capabilities and services of our two companies present a one-stop solution to pharmaceutical, biotech, and virtual pharmaceutical companies looking for a single reliable partner that can provide API and drug product development for preclinical and clinical studies,” said Maxime Laugier, Development and Projects Director at Creapharm Parenterals.
Total Page Views: 1199
